A Novel Pan Inhibitor of Bcl-2 and Mcl-1 Apogossypolone (apog2) with Superior Stability and Improved Activity Against Human Leukemia and Lymphoma Cells.

Yan Zhang,Yanqiong Lin,Ping Min,Xiongwen Zhang,Xiaolan Ling,Jay Stoudemire,Ming Guo,Dajun Yang

2007-01-01

Abstract:5182 Bcl-2 family of proteins are over-expressed in many cancers including leukemia and lymphoma, and it’s now recognized that overexpression of Bcl-2 family proteins plays an important role in the resistance to current anti-cancer therapies and is associated with unfavorable outcome. Gossypol is a polyphenolic aldehyde occurring naturally in cottonseed that has been extensively investigated as a male contraceptive agent, was recently discovered as a potent pan inhibitor of Bcl-2 family proteins. To overcome the potential non-specific toxicity related to the two reactive aldehyde groups in gossypol, we designed and synthesized a novel apogossypolone (ApoG2) in which the two aldehyde groups of gossypol are completely removed. We showed previously that ApoG2 exhibited more potent binding to Bcl-2 proteins, with Ki value of 25 nM for Mcl-1, Ki value of 35 nM for Bcl-2, respectively. In this study, we compared the stability, tolerance and antiproliferation effects in four human leukemia and lymphoma cells (HL-60, U937, K562, and Raji). Each sample of stability tests was evaluated for spectral purity using a proposed HPLC method and an HPLC system equipped with UV detector. The results showed that ApoG2 is very stable in the solid states upon standing at room temperatures for at least three weeks, and in various vehicles such as CMC (carboxymethylcellulose), DMSO and sesame oil. More importantly, when gossypols and ApoG2 were subjected to stress conditions of acid, base, peroxide and light, ApoG2 is the only stable compound resistant to acid, base, peroxide and light among gossypol and gossypol derivatives. The cytotoxicity was assessed in cell cultures derived from leukaemia and lymphoma using the tetrazolium-based WST viability assay. ApoG2 induced a dose-dependent cell killing effect in all cell lines with a mean IC50 of 1-3 μM at 72 hours and was significantly more potent than the racemic gossypol. In vitro, ApoG2 also demonstrated strong synergy with various kinase inhibitors in multiple cancer cell lines. Furthermore, ApoG2 was investigated in both mice and rats for maximal tolerated dose (MTD), and the data indicate that ApoG2 was significantly more tolerable than gossypol with MTD dose at more than 2,000 mg/kg level in a multi-dosing schedule. Preliminary studies using one gastric cancer xenograft model showed that ApoG2 is orally active against tumor proliferation in vivo. These investigations suggest that a novel and potent derivative of gossypol without aldehyde functional groups such as ApoG2 may have therapeutic potential for human leukemia/lymphoma and solid tumors either as a single agent or in a combination regimen.